A piece of street art known as "Tantawi's underwear" mocks Field Marshal Hussein Tantawi, who heads the ruling transitional military council.
Credit Adham Bakry
After the revolution, graphic artist Adham Bakry began stenciling the face of Safwat El Sherif, a member of Egypt's former ruling party, behind bars. El Sherif was arrested on corruption charges soon after. Bakry sees the rise of Cairo's street art as a push back against those who use the uprising as a marketing tool.
The revolution will be marketed!
Egyptian companies and multi-nationals are now using images of and references to the youth-led uprising that toppled autocrat Hosni Mubarak in advertisements to sell internet service, mobile phones, soft drinks, tourism and more.
The marketing has sparked something of a backlash among young Egyptians and has contributed to a rise in politicized street art and graffiti. Some street artists hope to reclaim the message in the streets by breaking the taboo of criticizing Egypt's military rulers.
The Pacific Northwest is suffering from too much of a good thing — electricity. It was a snowy winter and a wet spring, and there's lots of water behind the dams on the Columbia River, creating an oversupply of hydropower. As a result, the region's new wind farms are being ordered to throttle back — and they're not happy.
Martin Schreibman with a few of his tilapia friends in his Brooklyn lab.
It's a tough time for seafood lovers.
Prefer your fish from the ocean? That habitat is becoming a less hospitable place every day, according to a recent international State of the Oceans report. Water is getting warmer, more acidic. Dead zones are growing. A mass extinction of certain fish and coral species could happen sooner than scientists previously thought.
Doheny Beach in Orange County, Calif., photographed in 2005. A report on pollution at the nation's beaches found that Doheny failed at least one water quality standard 42 percent of the time it was tested in 2010.
In an unprecedented public hearing, a panel of experts advising the Food and Drug Administration considered whether the pricey drug Avastin should keep its approval for the treatment of breast cancer. The agency is moving to pull the approval for that use, and we talk about the outcome of the hearing in this week's podcast.